Detalhe da pesquisa
1.
Somatic activating ARAF mutations in Langerhans cell histiocytosis.
Blood
; 123(20): 3152-5, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24652991
2.
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Genes Chromosomes Cancer
; 54(6): 361-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25899310
3.
Intact IFN-γR1 expression and function distinguishes Langerhans cell histiocytosis from mendelian susceptibility to mycobacterial disease.
J Clin Immunol
; 34(1): 84-93, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24254535
4.
Erratum to: Intact IFN-γR1 Expression and Function Distinguishes Langerhans Cell Histiocytosis From Mendelian Susceptibility to Mycobacterial Disease.
J Clin Immunol
; 36(2): 171-2, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26783113
5.
Tertiary lymphoid structures are confined to patients presenting with unifocal Langerhans Cell Histiocytosis.
Oncoimmunology
; 5(8): e1164364, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622056
6.
The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome.
Oncoimmunology
; 5(3): e1084463, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28255525
7.
Activated Conventional T-Cells Are Present in Langerhans Cell Histiocytosis Lesions Despite the Presence of Immune Suppressive Cytokines.
J Interferon Cytokine Res
; 35(10): 831-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26381039